Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Neutral 63.1%

Neg 0% Neu 63.1% Pos 0%

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and lowers the price target from $11 to $10.